Cue Biopharma (NASDAQ:CUE) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• Cue Biopharma has received a "sell (D-)" rating from Weiss Ratings, indicating a negative outlook from analysts.
• The company reported a loss of $0.09 per share in its latest quarterly earnings, which was better than the anticipated loss of $0.13 per share.
• Shares of Cue Biopharma experienced a 3.0% decline in trading, with current stock priced at $0.79 and a market cap of $60.79 million.

Cue Biopharma (NASDAQ:CUE - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Cue Biopharma Stock Down 3.0%

Shares of Cue Biopharma stock traded down $0.02 during trading on Tuesday, hitting $0.79. 112,169 shares of the stock traded hands, compared to its average volume of 248,743. The firm has a market cap of $60.79 million, a P/E ratio of -1.41 and a beta of 1.55. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. Cue Biopharma has a 52-week low of $0.54 and a 52-week high of $1.99. The stock's fifty day simple moving average is $0.78 and its 200 day simple moving average is $0.75.

Cue Biopharma (NASDAQ:CUE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04. The firm had revenue of $2.95 million for the quarter, compared to analyst estimates of $2.00 million. Cue Biopharma had a negative return on equity of 230.13% and a negative net margin of 469.35%. On average, equities analysts predict that Cue Biopharma will post -0.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cue Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in CUE. Chicago Partners Investment Group LLC purchased a new position in Cue Biopharma in the first quarter valued at about $82,000. GC Wealth Management RIA LLC purchased a new position in Cue Biopharma in the second quarter valued at about $2,273,000. Angeles Wealth Management LLC purchased a new position in Cue Biopharma in the second quarter valued at about $82,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company's stock valued at $57,000 after purchasing an additional 73,000 shares during the last quarter. Hedge funds and other institutional investors own 35.04% of the company's stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.